Autoimmune gastrointestinal dysmotility market seen reaching $2.63B by 2030

By AI, Created 11:17 AM UTC, May 20, 2026, /AGP/ – The Business Research Company says the autoimmune gastrointestinal dysmotility market will grow from $1.82 billion in 2025 to $2.63 billion by 2030, driven by better diagnostics, personalized medicine and more research. North America held the biggest share in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Autoimmune gastrointestinal dysmotility is a rare condition, but it can severely disrupt digestion and quality of life. - Market growth signals rising demand for diagnostics, treatments and long-term care for patients with motility disorders linked to autoimmune disease. - The forecast also reflects broader momentum in personalized medicine and autoimmune research.

What happened: - The Business Research Company projected the autoimmune gastrointestinal dysmotility market will rise from $1.82 billion in 2025 to $1.92 billion in 2026. - The report says the market will reach $2.63 billion by 2030, implying an 8.2% compound annual growth rate. - The report was published May 8, 2026. - The company also offers a free sample of the report and the full market report.

The details: - Autoimmune gastrointestinal dysmotility, or AGID, is a rare condition in which the immune system attacks nerves that control digestive tract movement. - Symptoms include nausea, bloating, constipation and intestinal blockage. - AGID often appears alongside other autoimmune diseases or as part of a paraneoplastic syndrome, which can make diagnosis and treatment harder. - The report links near-term market growth to better autoimmune diagnosis, the prevalence of gastroparesis, more hospital gastroenterology services, greater use of immunosuppressive drugs and higher awareness of rare diseases. - Longer-term growth drivers include earlier diagnostic techniques, personalized therapy, demand for long-term care, growth in home-based nutrition therapies and broader autoimmune research. - The report says rising clinical trials are helping the market by speeding evaluation of drugs, biologics, devices and treatment protocols. - ClinicalTrials.gov showed registered trials increased from 477,203 at the end of 2023 to 520,877 at the end of 2024, a 9.1% increase. - The report also points to personalized medicine as a growth driver because genomics can help match treatments to individual patients and reduce side effects. - The Personalized Medicine Coalition said the U.S. FDA approved 26 personalized medicines in 2023, up from 12 in 2022. - Rising autoimmune disease rates are also expanding the treatment pool. - A 2024 review in Signal Transduction and Targeted Therapy estimated about 8.4 million people worldwide have rheumatoid arthritis. - The review said rheumatoid arthritis incidence is rising 2% to 3% a year and could affect 13.5 million to 17.4 million people by 2040. - In 2025, North America held the largest share of the market. - The report says Asia-Pacific will likely post the fastest growth. - The report also covers Western Europe, Eastern Europe, South America, the Middle East, Africa and Southeast Asia.

Between the lines: - The market outlook is less about a single therapy and more about a cluster of trends: better detection, more trial activity and wider use of individualized treatment. - The combination of rare-disease awareness and expanding autoimmune research suggests AGID is moving from a niche clinical issue toward a more defined commercial category. - Regional growth expectations imply the highest upside may be outside the current market leader, especially where healthcare investment and diagnostics are improving.

What’s next: - More clinical trial activity could produce additional drug and device options for AGID patients. - Continued expansion in personalized medicine may shape how clinicians diagnose and treat autoimmune motility disorders. - The company is also promoting related reports on autoimmune disease diagnosis, autoimmune treatment and veterinary autoimmune disease therapeutics.

The bottom line: - The autoimmune gastrointestinal dysmotility market is still small, but the report forecasts steady growth through 2030 as diagnostics, research and individualized care advance.